# Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine

> **NCT00500721** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 22 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HCV-796
- **DRUG:** Desipramine

## Key facts

- **NCT ID:** NCT00500721
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2008-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00500721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00500721, "Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00500721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*